My laboratory focuses on the development of mouse models in which cancer can be induced and studied during its early stages of growth and metastatic progression. We are also involved in the study of genetic alterations and their roles in cancer progression as well as the development of drug resistance to targeted therapy. Our research has yielded several key insights into the molecular mechanisms of cancer. Our most significant contributions include: development of the first genetically defined mouse model of ovarian carcinoma; elucidation of the genetic events that are sufficient for the transformation of normal ovarian surface epithelial cells in the mouse; demonstration that the ovarian surface epithelium can serve as a precursor tissue for serous ovarian carcinoma; demonstration that specific molecular pathways collaborate in ovarian cancer induction and progression and that alternative signaling pathways play a role in resistance to targeted therapy; generation of the first syngeneic BRCA1-deficient ovarian cancer cell lines; development of a transgenic mouse model for uterine leiomyosarcoma, an aggressive cancer type for which there is no effective therapy; and identification of molecular markers for individualized therapeutic strategies in ovarian cancer. My laboratory continues to make strides towards a better understanding of ovarian cancer and we are positioning ourselves to become proficient in progressive areas of cancer research, such as the tumor microenvironment, immunomodulation, chromatin reprogramming and determinants of cell differentiation.